Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update

K. R. Crews, A. Gaedigk, H. M. Dunnenberger, J. S. Leeder, T. E. Klein, K. E. Caudle, C. E. Haidar, D. D. Shen, John Callaghan, S. Sadhasivam, C. A. Prows, E. D. Kharasch, Todd Skaar

Research output: Contribution to journalArticle

302 Citations (Scopus)

Abstract

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume95
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Codeine
Cytochrome P-450 CYP2D6
Pharmacogenetics
Genotype
Guidelines
Therapeutics
Morphine
Opioid Analgesics
Safety
Liver

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy : 2014 Update. / Crews, K. R.; Gaedigk, A.; Dunnenberger, H. M.; Leeder, J. S.; Klein, T. E.; Caudle, K. E.; Haidar, C. E.; Shen, D. D.; Callaghan, John; Sadhasivam, S.; Prows, C. A.; Kharasch, E. D.; Skaar, Todd.

In: Clinical Pharmacology and Therapeutics, Vol. 95, No. 4, 2014, p. 376-382.

Research output: Contribution to journalArticle

Crews, KR, Gaedigk, A, Dunnenberger, HM, Leeder, JS, Klein, TE, Caudle, KE, Haidar, CE, Shen, DD, Callaghan, J, Sadhasivam, S, Prows, CA, Kharasch, ED & Skaar, T 2014, 'Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update', Clinical Pharmacology and Therapeutics, vol. 95, no. 4, pp. 376-382. https://doi.org/10.1038/clpt.2013.254
Crews, K. R. ; Gaedigk, A. ; Dunnenberger, H. M. ; Leeder, J. S. ; Klein, T. E. ; Caudle, K. E. ; Haidar, C. E. ; Shen, D. D. ; Callaghan, John ; Sadhasivam, S. ; Prows, C. A. ; Kharasch, E. D. ; Skaar, Todd. / Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy : 2014 Update. In: Clinical Pharmacology and Therapeutics. 2014 ; Vol. 95, No. 4. pp. 376-382.
@article{d717aae5b431465b97b931656b36f1b0,
title = "Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update",
abstract = "Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.",
author = "Crews, {K. R.} and A. Gaedigk and Dunnenberger, {H. M.} and Leeder, {J. S.} and Klein, {T. E.} and Caudle, {K. E.} and Haidar, {C. E.} and Shen, {D. D.} and John Callaghan and S. Sadhasivam and Prows, {C. A.} and Kharasch, {E. D.} and Todd Skaar",
year = "2014",
doi = "10.1038/clpt.2013.254",
language = "English",
volume = "95",
pages = "376--382",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy

T2 - 2014 Update

AU - Crews, K. R.

AU - Gaedigk, A.

AU - Dunnenberger, H. M.

AU - Leeder, J. S.

AU - Klein, T. E.

AU - Caudle, K. E.

AU - Haidar, C. E.

AU - Shen, D. D.

AU - Callaghan, John

AU - Sadhasivam, S.

AU - Prows, C. A.

AU - Kharasch, E. D.

AU - Skaar, Todd

PY - 2014

Y1 - 2014

N2 - Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

AB - Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

UR - http://www.scopus.com/inward/record.url?scp=84897022750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897022750&partnerID=8YFLogxK

U2 - 10.1038/clpt.2013.254

DO - 10.1038/clpt.2013.254

M3 - Article

C2 - 24458010

AN - SCOPUS:84897022750

VL - 95

SP - 376

EP - 382

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -